

Special Issue

Theranostic Drug Delivery: Prospects and Problems 2.0

Message from the Guest Editor

After the success of the first Special Issue on "Theranostic Drug Delivery: Prospects and Problems", in which high-impact papers authored by eminent international scientists were published, we are now aiming to launch the second Special Issue on the topic. As an important aspect of modern medicine, the theranostic approach is the most advanced, scientifically based, and statistically approved therapeutic and diagnostic methodology. Applications in the diagnosis and treatment of viral diseases and different types of cancer are being developed worldwide. We invite innovative research papers and review articles reflecting the fields of in vitro diagnostics and prognostics as well as in vivo molecular therapeutics and molecular imaging. In addition, we welcome manuscripts on biosensors, image-guided therapy, translational medicine, personalized medicine, system biology, and a broad range of biomedical research, which can be applied to enhance theranostic applications.

Guest Editor

Prof. Dr. M. R. Mozafari

Australasian Nanoscience and Nanotechnology Initiative (ANNI),
Monash University LPO, Clayton 3800, Australia

Deadline for manuscript submissions

closed (31 May 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/131342

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).